PL3245224T3 - Polipeptydy wiążące il-17a - Google Patents
Polipeptydy wiążące il-17aInfo
- Publication number
- PL3245224T3 PL3245224T3 PL16700424T PL16700424T PL3245224T3 PL 3245224 T3 PL3245224 T3 PL 3245224T3 PL 16700424 T PL16700424 T PL 16700424T PL 16700424 T PL16700424 T PL 16700424T PL 3245224 T3 PL3245224 T3 PL 3245224T3
- Authority
- PL
- Poland
- Prior art keywords
- binding polypeptides
- polypeptides
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15150786 | 2015-01-12 | ||
| EP16700424.1A EP3245224B1 (en) | 2015-01-12 | 2016-01-12 | Il-17a-binding polypeptides |
| PCT/EP2016/050456 WO2016113246A1 (en) | 2015-01-12 | 2016-01-12 | Il-17a-binding polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3245224T3 true PL3245224T3 (pl) | 2021-01-25 |
Family
ID=52339024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16700424T PL3245224T3 (pl) | 2015-01-12 | 2016-01-12 | Polipeptydy wiążące il-17a |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10934335B2 (enExample) |
| EP (3) | EP4643955A2 (enExample) |
| JP (3) | JP6943764B2 (enExample) |
| KR (2) | KR20240110106A (enExample) |
| CN (1) | CN108064235A (enExample) |
| AU (1) | AU2016208161B2 (enExample) |
| CA (1) | CA2972683A1 (enExample) |
| DK (1) | DK3245224T3 (enExample) |
| ES (1) | ES2822431T3 (enExample) |
| HU (1) | HUE052121T2 (enExample) |
| IL (1) | IL253004B (enExample) |
| MX (1) | MX394167B (enExample) |
| MY (1) | MY188784A (enExample) |
| NZ (1) | NZ732978A (enExample) |
| PL (1) | PL3245224T3 (enExample) |
| PT (1) | PT3245224T (enExample) |
| RU (1) | RU2749712C2 (enExample) |
| WO (1) | WO2016113246A1 (enExample) |
| ZA (1) | ZA201704366B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| CN108949789A (zh) * | 2018-06-26 | 2018-12-07 | 山东兴瑞生物科技有限公司 | 抗gcc的核酸、其制备方法、具有该核酸的免疫细胞及其应用 |
| CN120025437A (zh) * | 2019-01-31 | 2025-05-23 | 努玛治疗有限公司 | 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法 |
| US20220389066A1 (en) * | 2019-11-05 | 2022-12-08 | Affibody Ab | Polypeptides |
| CN111856029B (zh) * | 2020-06-19 | 2023-09-26 | 北华大学 | Il-17a蛋白在膀胱癌中的应用 |
| CN118632866A (zh) * | 2022-02-08 | 2024-09-10 | 阿菲博迪公司 | 结合胸腺基质淋巴细胞生成素的蛋白质z变体及其医疗用途 |
| WO2023196913A2 (en) | 2022-04-07 | 2023-10-12 | Acelyrin, Inc. | Methods of treating ankylosing spondylitis |
| EP4504235A4 (en) * | 2022-04-07 | 2025-11-19 | Acelyrin Inc | TREATMENT METHODS FOR HIDRADENITIS SUPPURATIVE |
| WO2024227930A1 (en) * | 2023-05-04 | 2024-11-07 | Affibody Ab | New polypeptide |
| CN116466095B (zh) * | 2023-06-15 | 2023-09-01 | 朗肽生物制药股份有限公司 | 一种多肽及其应用 |
| WO2025054498A1 (en) * | 2023-09-08 | 2025-03-13 | Acelyrin, Inc. | Methods of treating hidradenitis suppurativa |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| DK1963368T6 (da) | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| CA2675137A1 (en) | 2007-01-12 | 2008-07-24 | Sea Lane Biotechnologies, Llc. | Combinatorial libraries of conformationally constrained polypeptide sequences |
| DE08786222T1 (de) | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| ES2373832T3 (es) * | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| PE20160653A1 (es) * | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| EP2544785B1 (en) * | 2010-03-08 | 2015-09-30 | GE Healthcare Bio-Sciences AB | Immunoglobulin g fc region binding polypeptide |
| CN110437321A (zh) | 2010-07-09 | 2019-11-12 | 阿菲博迪公司 | 多肽 |
| WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
| EP2597102A1 (en) * | 2011-11-25 | 2013-05-29 | Covagen AG | A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 |
| WO2013126006A1 (en) * | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
| EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
| JP6590695B2 (ja) | 2012-09-25 | 2019-10-16 | アフィボディ・アーベー | アルブミン結合ポリペプチド |
| KR102151289B1 (ko) * | 2012-10-25 | 2020-09-02 | 애피바디 에이비 | Abd 결합 폴리펩티드 |
| AU2014207321A1 (en) | 2013-01-21 | 2015-07-23 | Abbvie Inc. | Anti-TNF and anti-IL17 combination therapy biomarkers for inflammatory disease |
| CA2902657C (en) * | 2013-03-15 | 2022-05-10 | Affibody Ab | Fcrn binding polypeptides |
| WO2015091957A1 (en) | 2013-12-20 | 2015-06-25 | Affibody Ab | Engineered albumin binding polypeptide |
-
2016
- 2016-01-12 KR KR1020247022438A patent/KR20240110106A/ko active Pending
- 2016-01-12 JP JP2017535976A patent/JP6943764B2/ja active Active
- 2016-01-12 KR KR1020177021726A patent/KR102683288B1/ko active Active
- 2016-01-12 DK DK16700424.1T patent/DK3245224T3/da active
- 2016-01-12 RU RU2017127012A patent/RU2749712C2/ru active
- 2016-01-12 PT PT167004241T patent/PT3245224T/pt unknown
- 2016-01-12 EP EP25184869.3A patent/EP4643955A2/en active Pending
- 2016-01-12 MX MX2017008660A patent/MX394167B/es unknown
- 2016-01-12 NZ NZ732978A patent/NZ732978A/en unknown
- 2016-01-12 EP EP16700424.1A patent/EP3245224B1/en active Active
- 2016-01-12 WO PCT/EP2016/050456 patent/WO2016113246A1/en not_active Ceased
- 2016-01-12 ES ES16700424T patent/ES2822431T3/es active Active
- 2016-01-12 AU AU2016208161A patent/AU2016208161B2/en active Active
- 2016-01-12 CA CA2972683A patent/CA2972683A1/en active Pending
- 2016-01-12 PL PL16700424T patent/PL3245224T3/pl unknown
- 2016-01-12 US US15/538,890 patent/US10934335B2/en active Active
- 2016-01-12 CN CN201680011379.3A patent/CN108064235A/zh active Pending
- 2016-01-12 EP EP20180610.6A patent/EP3738976B1/en active Active
- 2016-01-12 MY MYPI2017702236A patent/MY188784A/en unknown
- 2016-01-12 HU HUE16700424A patent/HUE052121T2/hu unknown
-
2017
- 2017-06-19 IL IL253004A patent/IL253004B/en active IP Right Grant
- 2017-06-27 ZA ZA2017/04366A patent/ZA201704366B/en unknown
-
2020
- 2020-12-17 JP JP2020209139A patent/JP7208963B2/ja active Active
-
2021
- 2021-02-01 US US17/163,961 patent/US12221464B2/en active Active
-
2023
- 2023-01-06 JP JP2023001177A patent/JP7456024B2/ja active Active
-
2024
- 2024-07-31 US US18/790,379 patent/US20250101074A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201802261B (en) | Polypeptides | |
| IL262482A (en) | New polypeptides | |
| IL255767A (en) | New polypeptides | |
| IL254577A0 (en) | polypeptides | |
| ZA201704366B (en) | Il-17a-binding polypeptides | |
| GB201611530D0 (en) | Novel polypeptides | |
| SG11201706882VA (en) | Polypeptides | |
| ZA201701348B (en) | New polypeptides | |
| GB201520539D0 (en) | Peptides | |
| GB201520543D0 (en) | Peptides | |
| GB201520536D0 (en) | Peptides | |
| GB201619652D0 (en) | Novel polypeptides | |
| GB201520545D0 (en) | Peptides | |
| GB201520603D0 (en) | Peptides | |
| GB201520541D0 (en) | Peptides | |
| GB201520568D0 (en) | Peptides | |
| GB201520542D0 (en) | Peptides | |
| GB201520558D0 (en) | Peptides | |
| IL246533A0 (en) | new proteins | |
| GB201515245D0 (en) | Novel polypeptides | |
| GB201403024D0 (en) | Polypeptides | |
| GB201520565D0 (en) | Peptides | |
| GB201520535D0 (en) | Peptides | |
| GB201520585D0 (en) | Peptides | |
| GB201520591D0 (en) | Peptides |